CLINICAL_TRIALS
trial_result
· 2020-02-27
Clinical Trial Update: Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) [Phase 3]
Summary
Phase III trial update for PXT3003 in Charcot-Marie-Tooth Disease Type 1A (PLEO-CMT) has completed with results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pharnext S.C.A. | Conditions: Charcot-Marie-Tooth Disease Type 1A | Phase 3 | Status: COMPLETED | Results posted: 2020-02-27